Evidence map›Paper›PMID 35036637›Full record

ArticleAdvances in radiation oncology

Development of an Orthotopic Murine Model of Rectal Cancer in Conjunction With Targeted Short-Course Radiation Therapy.

Taylor P Uccello, Sarah A Kintzel, Bradley N Mills, Joseph D Murphy, Jesse Garrett-Larsen, Nicholas G Battaglia, Carlos J Rodriguez, Michael G Drage, Jian Ye, Tanzy M T Love and 6 more

Open access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Radiation Therapy Exacerbates Tumor-Promoting Innervation and Nerve Signaling in Rectal Cancer.International journal of radiation oncology, biology, physics · 2023
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Taylor P UccelloDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York.
Sarah A KintzelDepartment of Biomedical Engineering, University of Rochester Medical Center, Rochester, New York.
Bradley N MillsDepartment of Surgery, University of Rochester Medical Center, Rochester, New York.
Joseph D MurphyDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York.
Jesse Garrett-LarsenDepartment of Surgery, University of Rochester Medical Center, Rochester, New York.
Nicholas G BattagliaDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York.
Carlos J RodriguezDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York.
Michael G DrageDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York.
Jian YeDepartment of Surgery, University of Rochester Medical Center, Rochester, New York.
Tanzy M T LoveDepartment of Biostatistics and Computational Biology, University of Rochester, Rochester, New York.
Carl J JohnstonDepartment of Pediatrics, University of Rochester Medical Center, Rochester, New York.
Elizabeth A RepaskyRoswell Park Comprehensive Cancer Center, University at Buffalo, Buffalo, New York.
Haoming QiuDepartment of Radiation Oncology, University of Rochester Medical Center, Rochester, New York.
David C LinehanDepartment of Surgery, University of Rochester Medical Center, Rochester, New York.
Edith M LordDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York.
Scott A GerberDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York.
University of Rochester Medical Center · USRoswell Park Comprehensive Cancer Center · USUniversity of Rochester · US

Funding

VISUAL INDICES OF NEUROTOXICITYP30ES001247 · NIEHS · UNIVERSITY OF ROCHESTER · PI Martha Susiarjo · 1985 to 2026
$42.8M
The T32 Predoctoral Training Program in Immunology (PTPI)T32AI007285 · NIAID · UNIVERSITY OF ROCHESTER · PI Scott Andrew Gerber, JACQUES Robert · 1986 to 2026
$7.6M
Targeting adrenergic stress pathways to Increase tumor sensitivity to radiation and promote development of an anti-tumor immune responseR01CA236390 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI GERBER, SCOTT ANDREW, REPASKY, ELIZABETH A · 2019 to 2023
$2.8M
Development of a New Strategy to Treat Locally Advanced Pancreatic CancerR01CA230277 · NCI · UNIVERSITY OF ROCHESTER · PI GERBER, SCOTT ANDREW · 2019 to 2023
$2.0M
NCI NIH HHS R01 CA230277NCI NIH HHS R01 CA236390NIAID NIH HHS T32 AI007285NIEHS NIH HHS P30 ES001247
6 · The paper itself

Abstract

purposeOrthotopic tumors more closely recapitulate human cancers than do ectopic models; however, precision targeting of such internal tumors for radiation therapy (RT) without inducing systemic toxicity remains a barrier. We developed an innovative murine orthotopic rectal tumor model where the insertion of clinical grade titanium fiducial clips on opposing sides of the rectal tumor allowed for targeted administration of short-course radiation therapy (SCRT). With this novel approach, clinically relevant RT regimens can be administered to orthotopic tumors to explore the biology and efficacy of radiation alone or as a combination therapy in a murine model that closely recapitulates human disease. METHODS AND MATERIALS: Murine Colon 38-luciferase tumor cells were injected into the rectal wall of syngeneic mice, and fiducial clips were applied to demarcate the tumor. An SCRT regimen consisting of 5 consecutive daily doses of 5 Gy delivered by an image-guided conformal small animal irradiator was administered 9 days after implantation. Tumor burden and survival were monitored along with histological and flow cytometric analyses on irradiated versus untreated tumors at various time points.

resultsSCRT administered to orthotopic rectal tumors resulted in a reduction in tumor burden and enhanced overall survival with no apparent signs of systemic toxicity. This treatment paradigm resulted in significant reductions in tumor cellularity and increases in fibrosis and hyaluronic acid production, recapitulating the SCRT-induced effects observed in human cancers.

conclusionsWe have established a means to target murine orthotopic rectal tumors using fiducial markers with a fractionated and clinically relevant SCRT schedule that results in an RT response similar to what is observed in human rectal cancer. We also validated our model through examining various parameters associated with human cancer that are influenced by irradiation. This model can be used to further explore RT doses and scheduling, and to test combinatorial therapies.

Identifiers

PMID35036637
PMCPMC8749199
OpenAlexW4200405687

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.